Accurate Assessment of Adherence
The DOI matches its Crossref record, with a small difference in title or year; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background People with cystic fibrosis have a high treatment burden. While uncertainty remains about individual patient level of adherence to medication, treatment regimens are difficult to tailor, and interventions are difficult to evaluate. Self- and clinician-reported measures are routinely used despite criticism that they overestimate adherence. This study assessed agreement between rates of adherence to prescribed nebulizer treatments when measured by self-report, clinician report, and electronic monitoring suitable for long-term use. Methods Seventy-eight adults with cystic fibrosis were questioned about their adherence to prescribed nebulizer treatments over the previous 3 months. Self-report was compared with clinician report and stored adherence data downloaded from the I-Neb nebulizer system. Adherence measures were expressed as a percentage of the prescribed regimen, bias was estimated by the paired difference in mean (95% CI) patient and clinician reported and actual adherence. Agreement between adherence measures was calculated using intraclass correlation coefficients (95% CI), and disagreements for individuals were displayed using Bland-Altman plots. Results Patient-identified prescriptions matched the medical record prescription. Median self-reported adherence was 80% (interquartile range, 60%-95%), whereas median adherence measured by nebulizer download was 36% (interquartile range, 5%-84.5%). Nine participants overmedicated and underreported adherence. Media…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some trials also highlighted a possible ceiling effect (Quinn 2004; Wildman 2022), as their recruited participants had baseline adherence rates already higher than 'real world' adherence (Daniels 2011;Hoo 2019;Hoo 2020;Hoo 2021).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Daniels 2011
In the citing paper
“This is promising as it shows that the methodology is advancing alongside evidence that highlights the discrepancy between objective and subjective measures of adherence (Daniels 2011; Thorton”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Daniels 2011
In the citing paper
“The discrepancy between objective and subjective measurement has also been highlighted (Daniels 2011;Modi 2006b;Thorton 2013;Warnock 2020).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Daniels 2011
In the citing paper
“Trials using objective recorded measures suggest that adherence to inhaled therapies in people with CF is around 31% to 36% in adults (Daniels 2011;Hoo 2019;Hoo 2020;Hoo 2021)”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Daniels 2011
In the citing paper
“Despite previous research highlighting the discrepancy between objective and subjective methods of measuring adherence to inhaled therapies in people with CF (Daniels 2011; Thorton 2013; Warnock 2020), objective measures are rarely used in practice (Robinson 2020).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Daniels 2011
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Inhaled bronchodilators for cystic fibrosis
Halfhide, C. P., Evans, H. J., & Couriel, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003428.pub2 · Cited by 66
RetractedSTATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91037-8 · Cited by 16,856
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
The diagnosis of cystic fibrosis: A consensus statement
Rosenstein, B. J., & Cutting, G. R. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70344-0 · Cited by 1,086
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Evidence-based Assessment of Adherence to Medical Treatments in Pediatric Psychology
Quittner, A. L., Modi, A. C., Lemanek, K. L., Ievers-Landis, C. E., & Rapoff, M. A. (2008) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm064 · Cited by 329
Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma: What Gets in the Way?
Modi, A. C., & Quittner, A. L. (2006) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsj096 · Cited by 301
A multi-method assessment of treatment adherence for children with cystic fibrosis
Modi, A. C., Lim, C. S., Yu, N., Geller, D., Wagner, M. H., & Quittner, A. L. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.03.002 · Cited by 265
Treatment compliance in adults with cystic fibrosis.
Abbott, J., Dodd, M., Bilton, D., & Webb, A. K. (1994) · Thorax · doi:10.1136/thx.49.2.115 · Cited by 188
Research works printed but not linked: 3
- Dodd, 1998, The medical and economic consequences of non-compliance in clinical trials and in primary care [Abstract], Thorax, 53, A18
- Nikander, 2008, Use of I-Neb Insight to examine patient logging system data from a 3-month evaluation of the I-Neb AAD system, Respir Drug Del, 3, 735
- Prince, 2006, I-Neb Insight: a new tool for monitoring inhaled medication use, Eur Respir J, 28, 261s
Cited by
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Blaschke, T. F., Osterberg, L., Vrijens, B., & Urquhart, J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011711-113247 · Cited by 419
Nguyen, T.-M.-U., Caze, A. L., & Cottrell, N. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12194 · Cited by 417
Drug Delivery to the lungs: Challenges and Opportunities
Newman, S. P. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0037 · Cited by 328
Assessing medication adherence: options to consider
Lehmann, A., Aslani, P., Ahmed, R., Celio, J., Gauchet, A., Bedouch, P., Bugnon, O., Allenet, B., & Schneider, M. P. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9865-x · Cited by 318
“SIMpill system, MDILog [91], Doser CT [91], i-Neb Nebulizer [92], eye-drop monitor [93]), some can monitor several medications simultaneously (e.”
BackgroundMethodLongitudinal association between medication adherence and lung health in people with cystic fibrosis
Eakin, M. N., Bilderback, A., Boyle, M. P., Mogayzel, P. J., & Riekert, K. A. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.03.005 · Cited by 246
Merchant, R. K., Inamdar, R., & Quade, R. C. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2015.11.022 · Cited by 218
Bain, E. E., Shafner, L., Walling, D. P., Othman, A. A., Chuang-Stein, C., Hinkle, J., & Hanina, A. (2017) · JMIR mHealth and uHealth · doi:10.2196/mhealth.7030 · Cited by 163
Chan, A. H. Y., Reddel, H. K., Apter, A. J., Eakin, M. N., Riekert, K. A., & Foster, J. M. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.06.015 · Cited by 137
Steinkamp, J. M., Goldblatt, N., Borodovsky, J. T., LaVertu, A., Kronish, I. M., Marsch, L. A., & Schuman-Olivier, Z. (2019) · JMIR Mental Health · doi:10.2196/12493 · Cited by 106
Geboers, B., Brainard, J. S., Loke, Y. K., Jansen, C., Salter, C., Reijneveld, S. A., & de Winter, A. F. (2015) · BMC Public Health · doi:10.1186/s12889-015-2251-y · Cited by 125
Standards for the care of people with cystic fibrosis; establishing and maintaining health
Southern, K. W., Addy, C., Bell, S. C., Bevan, A., Borawska-Kowalczyk, U., Brown, C., Burgel, P., Button, B., Castellani, C., Chansard, A., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.12.002 · Cited by 125
“These include, in order of accuracy and validity: electronic data capture (EDC), medication possession ratio (MPR), regular phone diaries, self-reporting via apps or paper diaries and retrospective surveys [172,173].”
Cystic fibrosis microbiology: Advances in antimicrobial therapy
Waters, V., & Smyth, A. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.02.005 · Cited by 94
Goodfellow, N. A., Hawwa, A. F., Reid, A. J. M., Horne, R., Shields, M. D., & McElnay, J. C. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0038-7 · Cited by 115
Fibrous dysplasia and cemento-ossifying fibroma. A histologic spectrum.
Voytek, T. M., Ro, J. Y., Edeiken, J., & Ayala, A. G. (1995) · PubMed · Cited by 91
Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis. A Randomized Clinical Trial
Griese, M., Kappler, M., Eismann, C., Ballmann, M., Junge, S., Rietschel, E., Koningsbruggen-Rietschel, S. V., Staab, D., Rolinck‐Werninghaus, C., Mellies, U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0427oc · Cited by 81
Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis.
Hilliard, M. E., Eakin, M. N., Borrelli, B., Green, A., & Riekert, K. A. (2015) · Health Psychology · doi:10.1037/hea0000136 · Cited by 77
“The cMPR was selected as an objective assessment of adherence across a range of prescribed pulmonary medications because self-reported adherence has been shown to be highly inaccurate among people with CF (Daniels et al., 2011), and pharmacy-based adherence measures have been recommended for use above self-reported ad…”
Parental Depression and Pancreatic Enzymes Adherence in Children With Cystic Fibrosis
Barker, D. H., & Quittner, A. L. (2016) · Pediatrics · doi:10.1542/peds.2015-2296 · Cited by 75
Meghani, S. H., Leis, A. M., Chittams, J. L., Bruner, D. W., & Riegel, B. J. (2015) · Journal of Pain · doi:10.1016/j.jpain.2015.05.009 · Cited by 75
“3, 7, 10, 14, 19, 54 Thus , we compared analgesic adherence for cancer pain between African Americans and Whites longitudinally using Medication Event Monitoring System [MEMS TM ].”
The impact of medication adherence on lung health outcomes in cystic fibrosis
Eakin, M. N., & Riekert, K. A. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283659f45 · Cited by 78
Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis
Bishay, L. C., & Sawicki, G. S. (2016) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s95637 · Cited by 82
“26 Despite potential inconsistencies and inaccuracies, existing literature in CF generally indicates low overall adherence rates.”
InfluentialShah, N. M., Hawwa, A. F., Millership, J. S., Collier, P. S., Ho, P. C., Tan, M. L., Peake, D., Tirupathi, S., Bothwell, J. E., Bailie, N., et al. (2013) · Epilepsia · doi:10.1111/epi.12126 · Cited by 69
“The highest percentage of adherence was observed with parental reporting (94% adherence) reflecting the known overestimation of adherence using this method (Daniels et al., 2011; Modi et al., 2011a).”
Newman, S. P. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.873402 · Cited by 73
“The data provided by AAD nebulisers was found to give a more accurate record of actual adherence than either patient reporting or clinician assessment [101].”
MethodInhaled therapy in cystic fibrosis: agents, devices and regimens
Agent, P., & Parrott, H. (2015) · Breathe · doi:10.1183/20734735.021014 · Cited by 69
Foster, J. M., Smith, L., Usherwood, T., Sawyer, S. M., Rand, C. S., & Reddel, H. K. (2012) · Journal of Asthma · doi:10.3109/02770903.2012.684253 · Cited by 62
“In the context of severe asthma, the high cost or risk associated with new biological add-on therapies may justify expenditure on electronic monitoring as disentangling poor treatment response from poor adherence can be extremely difficult in clinical practice (17).”
BackgroundRelationship of adherence determinants and parental spirituality in Cystic Fibrosis
Grossoehme, D. H., Opipari‐Arrigan, L., VanDyke, R. D., Thurmond, S., & Seid, M. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21614 · Cited by 60
Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)
Harrison, M. J., McCarthy, M. M., Fleming, C., Hickey, C., Shortt, C., Eustace, J., Murphy, D. M., & Plant, B. J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.04.004 · Cited by 59
Medication adherence to oral anticancer drugs: systematic review
Huang, W., Chen, C., Lin, S., & Chang, C.-S. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1159515 · Cited by 60
Predictors of Adherence to Inhaled Medications Among Veterans with COPD
Huetsch, J., Uman, J. E., Udris, E. M., & Au, D. H. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2130-5 · Cited by 62
Adherence of Subjects With Cystic Fibrosis to Their Home Program: A Systematic Review
O'Donohoe, R., & Fullen, B. M. (2014) · Respiratory Care · doi:10.4187/respcare.02990 · Cited by 64
Marshall, B. C., & Nelson, E. C. (2014) · BMJ Quality & Safety · doi:10.1136/bmjqs-2013-002790 · Cited by 55
Wildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217594 · Cited by 54
“8 Problem-solving techniques can be used to overcome individual capability and opportunity barriers.”
Gandhi, K. K., Vu, B.-M. K., Eshtehardi, S. S., Wasserman, R. M., & Hilliard, M. E. (2015) · Diabetes Management · doi:10.2217/dmt.15.41 · Cited by 60
Nguyen, T., Caze, A. L., & Cottrell, N. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013375 · Cited by 60
Arden, M. A., Hutchings, M., Whelan, P., Drabble, S. J., Beever, D., Bradley, J. M., Hind, D., Ainsworth, J., Maguire, C., Cantrill, H., et al. (2021) · Pilot and Feasibility Studies · doi:10.1186/s40814-020-00739-2 · Cited by 44
Opportunities for cystic fibrosis care teams to support treatment adherence
Riekert, K. A., Eakin, M. N., Bilderback, A. L., Ridge, A. K., & Marshall, B. C. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.10.003 · Cited by 47
Advances in Audio-Based Systems to Monitor Patient Adherence and Inhaler Drug Delivery
Taylor, T. E., Zigel, Y., Looze, C. D., Sulaiman, I., Costello, R. W., & Reilly, R. B. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.1162 · Cited by 46
Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis
Nasr, S. Z., Chou, W., Villa, K. F., Chang, E., & Broder, M. S. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.787427 · Cited by 44
Moullec, G., Gour-Provençal, G., Bacon, S., Campbell, T. S., & Lavoie, K. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.06.001 · Cited by 52
Arden, M. A., Drabble, S., O'Cathain, A., Hutchings, M., & Wildman, M. (2019) · British Journal of Health Psychology · doi:10.1111/bjhp.12357 · Cited by 42
“(Daniels et al., 2011).”
BackgroundTackling the increasing complexity of CF care
Sawicki, G. S., & Goss, C. H. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23244 · Cited by 46
“Additionally, clinicians have over-estimated adherence in CF as well.(14) Prescription refills can serve as a measure of adherence, and several data sources have identified significant gaps in prescription refill rates for oral and inhaled medications.”
BackgroundTobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group
Geller, D. E., Nasr, S. Z., Piggott, S., He, E., Angyalosi, G., & Higgins, M. (2013) · Respiratory Care · doi:10.4187/respcare.02264 · Cited by 40
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
Hind, D., Drabble, S. J., Arden, M. A., Mandefield, L., Waterhouse, S., Maguire, C., Cantrill, H., Robinson, L., Beever, D., Scott, A. J., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0834-6 · Cited by 40
“self-reported and objectively measured adherence to inhaled therapy, with recorded rates of 80 and 36% respectively [14].”
Geller, D. E., & Madge, S. (2011) · Respiratory Medicine · doi:10.1016/s0954-6111(11)70024-5 · Cited by 39
Physiotherapy in cystic fibrosis: optimising techniques to improve outcomes
Rand, S., Hill, L., & Prasad, S. A. (2012) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2012.08.006 · Cited by 52
The pediatric asthma yardstick
Chipps, B. E., Bacharier, L. B., Farrar, J. R., Jackson, D. J., Murphy, K. R., Phipatanakul, W., Szefler, S. J., Teague, W. G., & Zeiger, R. S. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.04.002 · Cited by 47
Cystic fibrosis patient registries: A valuable source for clinical research
Dasenbrook, E. C., & Sawicki, G. S. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.03.001 · Cited by 36
“Clinicians also may overestimate an individual patient's adherence [44], and thus a registry may continue to document a prescribed treatment plan that is no longer being used.”
BackgroundCystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine
Sepahzad, A., Morris-Rosendahl, D. J., & Davies, J. C. (2021) · Genes · doi:10.3390/genes12040562 · Cited by 40
“Finally, one of the greatest contributors to health outcomes is adherence to prescribed therapies; studies of behaviour have demonstrated that healthcare professionals are poor both at estimating patient adherence [87] and at encouraging it.”
BackgroundAirway clearance techniques used by people with cystic fibrosis in the UK
Hoo, Z. H., Daniels, T. E., Wildman, M. J., Teare, M. D., & Bradley, J. M. (2015) · Physiotherapy · doi:10.1016/j.physio.2015.01.008 · Cited by 33
Self-citationPatterns of analgesic adherence predict health care utilization among outpatients with cancer pain
Meghani, S. H., & Knafl, G. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s93726 · Cited by 31
Fungal contamination of nebuliser devices used by people with cystic fibrosis
Peckham, D. G., Williams, K., Wynne, S., Denton, M., Pollard, K., & Barton, R. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.06.004 · Cited by 31
Self-citationEmerging Technologies for Electronic Monitoring of Adherence, Inhaler Competence, and True Adherence
Pritchard, J. N., & Nicholls, C. (2014) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2014.1163 · Cited by 33
Factors associated with false-positive self-reported adherence to antihypertensive drugs
Tedla, Y. G., & Bautista, L. E. (2016) · Journal of Human Hypertension · doi:10.1038/jhh.2016.80 · Cited by 30
Quittner, A. L., Eakin, M. N., Alpern, A. N., Ridge, A. K., McLean, K. A., Bilderback, A., Criado, K. K., Chung, S.-E., & Riekert, K. A. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.004 · Cited by 27
Hoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
“10 Although there is significant phenotypic variability for each class of CFTR mutation, the relationship between pancreatic status and genotype is more robust and the group with at least one class IV–”
Roche, N., Scheuch, G., Pritchard, J. N., Nopitsch-Mai, C., Lakhani, D. A., Saluja, B., Jamieson, J., Dundon, A., Wallace, R., Holmes, S., et al. (2016) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2016.1326 · Cited by 29
“(41,42) To enable appropriate patient education, physicians, nurses, and pharmacists also need to be educated so they understand not only different inhalation techniques but also the importance of using the correct technique.”
Peipert, J. D., Badawy, S. M., Baik, S. H., Oswald, L. B., Efficace, F., Garcia, S. F., Mroczek, D. K., Wolf, M. S., Kaiser, K., Yanez, B. R., et al. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s249079 · Cited by 29
Rouzé, H., Viprey, M., Allemann, S. S., Dima, A. L., Caillet, P., Denis, A., Bourdy, S., Camara, B., Llerena, C., Reix, P., et al. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s211769 · Cited by 33
Thee, S., Stahl, M., Fischer, R., Sutharsan, S., Ballmann, M., Müller, A., Lorenz, D., Urbanski-Rini, D., Püschner, F., Amelung, V. E., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01500-y · Cited by 25
Enhancing adherence to inhaled therapies in cystic fibrosis
Lomas, P. (2014) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465814524471 · Cited by 26
Pakhale, S. S., Baron, J., Armstrong, M. B., Tasca, G. A., Gaudet, E., Aaron, S. D., Cameron, D. W., & Balfour, L. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2016.03.023 · Cited by 26
White, H., Shaw, N., Denman, S., Pollard, K., Wynne, S., & Peckham, D. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.00987-2016 · Cited by 25
“Poor adherence to treatment remains a significant problem, being as low as 40 to 50%.[3-7] Adherence problems can negatively influence health outcomes such as pulmonary exacerbations,[8] health related quality of life,[3] and healthcare costs;[6-9] trends that are also apparent across other respiratory diseases.”
BackgroundMethodSelf-citationTappenden, P., Sadler, S., & Wildman, M. J. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0500-x · Cited by 24
“[7] (36% drug consumption in current CF care group) and Demonceau et al.”
BackgroundDrabble, S. J., O'Cathain, A., Scott, A. J., Arden, M. A., Keating, S., Hutchings, M., Maguire, C., & Wildman, M. (2020) · Journal of Medical Internet Research · doi:10.2196/16782 · Cited by 23
“Adherence to nebulizer treatments is often low, with objectively measured adherence found to average 36% compared with 80% estimated by patients [7].”
BackgroundWildman, M. J., & Hoo, Z. H. (2014) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2014.04.007 · Cited by 23
Alsous, M. M., Hamdan, I. I., Saleh, M., McElnay, J. C., Horne, R., & Masri, A. T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.06.022 · Cited by 29
Gao, J., Arden, M. A., Hoo, Z. H., & Wildman, M. J. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4260-5 · Cited by 23
Pruette, C. S., Coburn, S. S., Eaton, C. K., Brady, T. M., Tuchman, S., Mendley, S. R., Fivush, B. A., Eakin, M. N., & Riekert, K. A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-4044-x · Cited by 24
Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis
Oates, G. R., Štěpáníková, I., Rowe, S. M., Gamble, S., Gutierrez, H. H., & Harris, W. T. (2018) · Respiratory Care · doi:10.4187/respcare.06436 · Cited by 27
Smart dry powder inhalers and intelligent adherence management
Häußermann, S., Arendsen, L. J., & Pritchard, J. N. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114580 · Cited by 25
Predictors of medication adherence: fact or artifact
Dunbar‐Jacob, J. M., & Rohay, J. M. (2016) · Journal of Behavioral Medicine · doi:10.1007/s10865-016-9752-8 · Cited by 23
Mikesell, C. L., Kempainen, R. R., Laguna, T. A., Menk, J. S., Wey, A. R., Gaillard, P. R., & Regelmann, W. E. (2017) · Respiratory Care · doi:10.4187/respcare.05349 · Cited by 23
Hoo, Z. H., Boote, J., Wildman, M. J., Campbell, M. J., & Gardner, B. (2017) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2017.1338958 · Cited by 21
“However, in the US and UK, adherence is only around 30–50% (Daniels et al., 2011; Quittner et al., 2014).”
BackgroundInhaled Interventions in Cystic Fibrosis: Mucoactive and Antibiotic Therapies
Hurt, K., & Bilton, D. (2014) · Respiration · doi:10.1159/000369533 · Cited by 25
Geneti, Y., Desta, K. W., Adimasu, M., Deressa, D., Aga, F., Lami, M., Abdisa, L., Sori, S. A., & Jiru, H. D. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s350168 · Cited by 23
Eikholt, A. A., Wiertz, M. B. R., Hew, M. J., Chan, A. H. Y., & van Boven, J. F. M. (2023) · Current Treatment Options in Allergy · doi:10.1007/s40521-023-00328-7 · Cited by 20
Inhaled antibiotics in cystic fibrosis: what's new?
Hewer, S. L. (2012) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2012.12s004 · Cited by 20
Coppolo, D. P., SCHLOSS, J., Suggett, J. A., & Mitchell, J. P. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00178-1 · Cited by 28
Trajectories of physical functioning among US adults with cognitive impairment
Zang, E. X., Shi, Y., Wang, X., Wu, B., & Fried, T. R. (2022) · Age and Ageing · doi:10.1093/ageing/afac139 · Cited by 23
Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis
Lin, A. H.-A., Kendrick, J. G., Wilcox, P., & Quon, B. S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s129088 · Cited by 18
“Other barriers self-reported by patients include absence of perceived benefits and doubts about the necessity of treatment.(6,11,12) As such, patient knowledge is a potential determinant of pulmonary medication adherence because it influences perceived or anticipated medication benefits and the necessity of treatment.”
Hoo, Z. H., Campbell, M. J., Curley, R., Walters, S. J., & Wildman, M. J. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.10.005 · Cited by 18
Drabble, S. J., O’Cathain, A., Arden, M. A., Hutchings, M., Beever, D., & Wildman, M. J. (2019) · Qualitative Health Research · doi:10.1177/1049732319856580 · Cited by 24
“Rather than relying on self-reported adherence that may be inaccurate (Daniels et al., 2011), the use of objective adherence data from chipped nebulizers can help to open up patient-led discussions about adherence behavior.”
BackgroundAdherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia
Alsous, M. M., Farha, R. K. A., Alefishat, E. A., Omar, S. A., Momani, D., Gharabli, A., McElnay, J. C., Horne, R., & Rihani, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183119 · Cited by 21
Real-World Adherence Among Adults With Cystic Fibrosis Is Low
Hoo, Z. H., Totton, N., Waterhouse, S., Lewis, J., Girling, C., Bradburn, M. J., Arden, M. A., Whelan, P., Ainsworth, J. D., Dawson, S., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.039 · Cited by 21
Self-citationNorberg, H., Sjölander, M., Glader, E., & Gustafsson, M. V. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03284-4 · Cited by 24
A framework for understanding sources of bias in medication adherence research
Sinnappah, K. A., Hughes, D. A., Stocker, S. L., Vrijens, B., Aronson, J. K., & Wright, D. F. B. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15863 · Cited by 17
Hoo, Z. H., Curley, R., Walters, S. J., Campbell, M. J., & Wildman, M. J. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.008 · Cited by 18
“In other words, although reported adherence levels among adults with CF in the literature are low at 35-50% [3, 4], the actual total cohort effective adherence levels are almost certainly even lower.”
BackgroundMethodInfluentialKoningsbruggen-Rietschel, S. V., Heuer, H.-E., Merkel, N., Posselt, H., Staab, D., Sieder, C., Ziegler, J., Krippner, F., & Rietschel, E. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv399 · Cited by 17
Georgiopoulos, A. M., Friedman, D., Porter, E. A., Krasner, A., Kakarala, S. P., Glaeser, B. K., Napoleon, S. C., & Wozniak, J. R. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.08.011 · Cited by 20
Outcome evaluation of a pharmacy‐based therapy management program for patients with cystic fibrosis
Kirkham, H. S., Staskon, F. C., Hira, N., McLane, D., Kilgore, K. M., Parente, A., Kim, S., & Sawicki, G. S. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.23978 · Cited by 18
“Self-reported rates were generally higher compared to claims-based or electronic monitoring rates.(12) Although barriers to adherence change over a patient's lifetime,(5,11) lack of time is often a primary reason cited for nonadherence.”
ResultAirway clearance and exercise for people with cystic fibrosis: balancing longevity with life
Rowbotham, N. J., & Daniels, T. E. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25734 · Cited by 16
“shown to overestimate adherence in other areas of treatment for pwCF such as nebulized therapy.(27) Project Fizzyo is an ongoing longitudinal observational cohort study which is gathering objective”
BackgroundResultSelf-citationZheng, Y., Sereika, S. M., Ewing, L. J., Danford, C. A., Terry, M. A., & Burke, L. E. (2015) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2015.10.014 · Cited by 16
Greally, P., Whitaker, P., & Peckham, D. G. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.674500 · Cited by 21
Self-citationSánchez‐Viñas, A., Corral‐Partearroyo, C., Gil‐Girbau, M., Peñarrubia‐María, M. T., Gallardo‐Gonzalez, C., Olmos-Palenzuela, M. D. C., Aznar‐Lou, I., Serrano‐Blanco, A., & Rubio-Valera, M. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01727-6 · Cited by 17
Dawson, S., Girling, C.-J., Cowap, L., & Clark-Carter, D. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013766.pub2 · Cited by 14
Moore, J. E., Millar, B. C., Ollman-Selinger, M., & Cambridge, L. (2021) · Respiratory Care · doi:10.4187/respcare.08671 · Cited by 15
Bronchodilators in cystic fibrosis: a critical analysis
Barry, P. J., & Flume, P. A. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1246358 · Cited by 14
Antimicrobial prophylaxis for urinary tract infections: implications for adherence assessment
Gaither, T. W., & Copp, H. L. (2019) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2019.04.019 · Cited by 14
Hind, D., Drabble, S. J., Arden, M. A., Mandefield, L., Waterhouse, S., Maguire, C., Cantrill, H., Robinson, L., Beever, D., Scott, A. J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039089 · Cited by 17
Metadata
- Authors
- Daniels, T., Goodacre, L., Sutton, C., Pollard, K., Conway, S., & Peckham, D.
- Affiliations
- York Hospital (GB)
- University of Lancashire (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- Daniels, Tracey
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 140
- Issue
- 2
- Pages
- 425-432
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2086921502
- Cited by
- 210
- References
- 27
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 11 · 2023: 12 · 2022: 32 · 2021: 13 · 2020: 18 · 2019: 15 · 2018: 11 · 2017: 16 · 2016: 14 · 2015: 15 · 2014: 17 · 2013: 14 · 2012: 7
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- CLOK (University of Central Lancashire) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Keywords
- cystic fibrosis, medication adherence, electronic monitoring, self-report, treatment burden
- MeSH terms
- Adult, Cystic Fibrosis, Electronics, Female, Humans, Male, Nebulizers and Vaporizers, Medication Adherence, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.